Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06124846 · ClinicalTrials.gov registry record · NA
Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)
A NA study of Cannabis Use Disorder, sponsored by University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06124846: Recruiting NA study of Cannabis Use Disorder, sponsored by University of Minnesota.
NCT06124846 is a NA study of Cannabis Use Disorder that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 64 participants, below the 107-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06124846, a NA study of Cannabis Use Disorder, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-based activation during a Monetary Incentive Delay Task and fronto-striatal fMRI resting-state functional connectivity. The study will also explore self-reported impulsivity. The long-term goal is to advance scientific understanding of neural changes associated with cannabis abstinence and inter-individual variability that cannot be otherwise measured in preexisting observational cohorts such as the Adolescent Brain Cognitive Development Study. This parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. Utilizing a validated paradigm, adolescents with CUD will be randomized to 6-weeks of either incentivized, biochemically verified abstinence via contingency management or monitoring with no required abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol. Participants will complete 8 study visits (3 with fMRI scans) involving urinalysis to confirm cannabis self-report and measures of impulsivity. Participants may additionally and optionally (1) complete daily remote self-report assessments of cannabis use, impulsivity, and mood throughout the 6-week treatment period, and (2) continue participation for an additional 6-week monitoring period after the treatment period, during which they complete daily remote self-report assessments of cannabis use, impulsivity, and mood.
Primary Outcome
A neural measure of reward activation will be defined as the difference between reward positive vs negative feedback in the standardized Harvard Oxford Striatal atlas during the MID Task.
Conditions Studied
Interventions
- BEHAVIORAL CB-Abst
- BEHAVIORAL CB-Mon
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2028-04-15 |
| Phase | NA |
What NCT06124846 shows while recruiting
NCT06124846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 107-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which CB-Abst is the first listed.
NCT06124846 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06124846 about?
NCT06124846 is a clinical study titled "Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)". The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-b...
What is the current status of trial NCT06124846?
This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2024-04-01. Estimated completion is 2028-04-15.
What conditions does trial NCT06124846 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06124846?
The interventions under investigation include: CB-Abst (BEHAVIORAL), CB-Mon (BEHAVIORAL).
Who is sponsoring clinical trial NCT06124846?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06124846 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06124846's enrollment target sits among peer trials
64 22nd of 34 higher than 13 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV
RECRUITING · NA
-
A Brief Intervention for Cannabis Use
RECRUITING · NA
-
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
RECRUITING · NA
-
RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI